FDA approves Pfizer gene therapy Beqvez for treatment of hemophilia B

[Pelican Press 0]

FDA approves Pfizer gene therapy Beqvez for treatment of hemophilia B

The Food and ***** Administration

This is the hidden content, please

• Sign In
• or
• Sign Up

announced that the agency approved Pfizer‘s treatment for a rare genetic

This is the hidden content, please

• Sign In
• or
• Sign Up

, making it the company’s

This is the hidden content, please

• Sign In
• or
• Sign Up

to win clearance in the U.S. 

The agency

This is the hidden content, please

• Sign In
• or
• Sign Up

the *****, which will be marketed as Beqvez, for adults with moderate to severe

This is the hidden content, please

• Sign In
• or
• Sign Up

who meet certain

This is the hidden content, please

• Sign In
• or
• Sign Up

.

The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3.5 million price tag before insurance and other rebates, the spokesperson added, making it by far one of the most expensive drugs in the U.S.

More than 7,000 people in the U.S. are living with the debilitating

This is the hidden content, please

• Sign In
• or
• Sign Up

, which predominantly affects men, according to an

This is the hidden content, please

• Sign In
• or
• Sign Up

. The condition is caused by insufficient levels of a

This is the hidden content, please

• Sign In
• or
• Sign Up

that helps blood clot to stop bleeding and seal wounds. Without that protein, called factor IX, patients with hemophilia B bruise easily and bleed more frequently and for longer periods of time. 

Beqvez is a one-time treatment designed to enable patients to produce factor IX themselves and prevent and control bleeding. In a late-stage trial, the ***** was superior to the often-cumbersome

This is the hidden content, please

• Sign In
• or
• Sign Up

for hemophilia B, which involves administering the protein multiple times a week or a month through the veins. 

“Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular [factor IX] infusions, as well as spontaneous bleeding episodes, which can lead to painful ****** damage and mobility issues,” said Adam Cuker, director of Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, in a Pfizer

This is the hidden content, please

• Sign In
• or
• Sign Up

on Friday.

Pfizer’s ***** “has the potential to be transformative for appropriate patients by reducing both the medical and treatment burden over the long term,” Cuker added. 

The approval is a big step for Pfizer, which is trying to regain its footing following the rapid decline of its Covid business last year. The company is ******** big on ******* drugs and treatments for other ******** areas to help turn its business around. 

Pfizer is one of several companies to invest in the rapidly growing field of gene and cell therapies — one-time, high-cost treatments that target a patient’s genetic source or cell to cure or significantly alter the course of a ********. Some health experts expect these therapies to replace traditional lifelong treatments that people take to manage chronic *********. 

Pfizer

This is the hidden content, please

• Sign In
• or
• Sign Up

to produce and market Beqvez from Spark Therapeutics in 2014. 

The company is offering payers a warranty program to cover patients who receive Beqvez, a spokesperson told CNBC. Pfizer expects that program to offer “financial protection by insuring against the risk of efficacy ********,” the release said.

The gene therapy will compete with Australia-based CSL Behring’s

This is the hidden content, please

• Sign In
• or
• Sign Up

, a similar treatment that

This is the hidden content, please

• Sign In
• or
• Sign Up

for hemophilia B in 2022. That ***** has a similar list price of $3.5 million in the U.S. before insurance and other rebates. 

Notably, some health experts have said that high costs and logistical issues, among other factors, have

This is the hidden content, please

• Sign In
• or
• Sign Up

of Hemgenix and another approved gene therapy for the more common hemophilia A. 

Pfizer also seeks FDA approval for its experimental antibody, marstacimab, to treat hemophilia A and B. The company is also developing a gene therapy for Duchenne muscular dystrophy, a genetic disorder that causes muscles to weaken gradually. 

This is the hidden content, please

• Sign In
• or
• Sign Up

Breaking news,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Pfizer Inc,Science,******* States,business news
#FDA #approves #Pfizer #gene #therapy #Beqvez #treatment #hemophilia

This is the hidden content, please

• Sign In
• or
• Sign Up